BioNTech

德国mRNA双雄合体：BioNTech正式完成对CureVac的收购

angelina - January 7, 2026

BioNTech开启并购新纪元：整合CureVac mRNA技术，全力押注肿瘤疗法

Brett Shapiro - January 6, 2026

BioNTech股价：十字路口的机遇与挑战

kashif hafeez - January 1, 2026

BioNTech战略转型：后疫情时代的肿瘤学征途

Brett Shapiro - December 30, 2025

生物技术巨头战略转型：BioNTech全力押注肿瘤疗法新赛道

December 28, 2025

BioNTech战略转型：并购CureVac重塑mRNA产业格局

angelina - December 28, 2025

BioNTech Consolidates mRNA Sector with CureVac Acquisition Finalized

December 24, 2025

BioNTech’s Strategic Pivot: Merging Assets and Shifting Focus to Oncology

kashif hafeez - December 24, 2025

BioNTech Secures CureVac Acquisition Amid Market Indifference

angelina - December 19, 2025

BioNTech Shares: A Valuation Disconnect Amid Operational Progress

December 18, 2025

BioNTech’s Dual Strategy: M&A and Clinical Data Signal Oncology Shift

December 17, 2025

BioNTech’s Strategic Moves Spark Investor Reassessment

December 15, 2025

Institutional Investors Seize Opportunity in BioNTech’s Depressed Shares

angelina - December 13, 2025

Analysts See Significant Upside for BioNTech Shares

December 13, 2025

BioNTech Shares Navigate Sector Headwinds Amid Clinical Progress

angelina - December 11, 2025

123 4 Page 2 of 4